Acumen Pharmaceuticals announced a joint collaboration, option, and license agreement with JCR Pharmaceuticals to develop a novel therapeutic candidate for Alzheimer’s disease. This partnership leverages JCR’s proprietary J-Brain Cargo® blood-brain barrier (BBB)-penetrating technology platform. The collaboration aims to combine JCR’s technology with Acumen’s amyloid beta oligomer (AβO)-selective antibodies.
The program's goal is to demonstrate the feasibility of J-Brain Cargo® in delivering sabirnetug and other AβO-selective antibodies across the BBB to slow the progression of AD pathology. Under the terms, JCR will receive an upfront payment and be eligible for an additional option payment if Acumen exercises its exclusive option to develop, manufacture, and commercialize up to two candidates worldwide.
JCR is also eligible for future milestone payments of up to USD 40 million related to development and up to USD 515 million related to sales, totaling up to USD 555 million. Additionally, JCR will receive tiered royalties on net sales. Preclinical candidate data from this collaboration are expected in early 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.